scholarly journals The Wistar Institute Cancer Center

2020 ◽  
Author(s):  
Keyword(s):  
Cancer Center ◽  
Wistar Institute

scholarly journals Philadelphia and the Delaware Valley: A Geographically Distributed and Expanding Life Science Ecosystem

2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Dennis Gross
Keyword(s):  
University Of Pennsylvania ◽  
Cancer Center ◽  
Jefferson Medical College ◽  
Delaware Valley ◽  
Medical College ◽  
Temple University ◽  
Research Division ◽  
Wistar Institute ◽  
School Of Medicine ◽  
Drexel University

Philadelphia has been considered by many to be the birthplace of the modern US pharmaceutical industry with Merck & Co. Inc.’s research division Merck Research Labs [originally called MSDRL] based in West Point and GSK’s primary US labs [originally SKF] now based in Collegeville. The City of Philadelphia is also home to two of the oldest medical schools in the US: Perelman School of Medicine at the University of Pennsylvania founded in 1765 and the Sydney Kimmel Medical College [formerly Jefferson Medical College] founded in 1824. The conjunction of those two touchpoints along with the other big pharma players, e.g., Johnson & Johnson/Janssen and emerging biotech entities in the wider Delaware Valley region is significant. Also noteworthy is the presence of other research intensive universities such as Drexel University, Temple University, Jefferson University and research institutes such as the Wistar Institute, Fox Chase Cancer Center [associated with Temple University School of Medicine], Lankenau Institute, Monell Chemical Senses Center and the Coriell Institute in Southern New Jersey.

966: Radical Prostatectomy for Lymph Node Positive Prostate Cancer: The M.D. Anderson Cancer Center Experience

2006 ◽  
Vol 175 (4S) ◽  
pp. 311-312
Author(s):  
Philippe E. Spiess ◽  
Joseph E. Busby ◽  
Jennifer Jordan ◽  
Mike Hernandez ◽  
Patricia Troncoso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Cancer Center ◽  
Node Positive ◽  
Lymph Node Positive

ASCO-GU 2019: Fortgeschrittenes Nierenzellkarzinom

2019 ◽  
Vol 10 (02) ◽  
pp. 75-76
Author(s):  
Ine Schmale
Keyword(s):  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Washington Dc

Das Armamentarium zur Behandlung des Nierenzellkarzinoms (RCC) hat sich um effektive Therapien erweitert, durch die der Therapiealgorithmus komplett umgestellt werden musste. Prof. Michael B. Atkins vom Georgetown-Lombardi Comprehensive Cancer Center, Washington DC/USA, und Prof. Daniel Y. C. Heng vom Tom Baker Cancer Center, Calgary/Kanada, teilten beim ASCO-GU ihre Einschätzung zur optimalen Behandlung des Nierenzellkarzinoms in der Erst- und Zweitlinientherapie für das Jahr 2019.

Sign in / Sign up

Export Citation Format

Share Document